(Chemo)Radiotherapy–Immunotherapy Combinations: Time to Get Tailored?
Michele Mondini, Éric Deutsch
Abstract
Abstract Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification. See related article by Chen et al., p. 3990
Topics & Concepts
ChemoradiotherapyMedicineImmunotherapyRadiation therapyCervical cancerOncologyCancer treatmentCancer immunotherapyCancerInternal medicineCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune Cell Function and Interaction